Table 2.
Normalized oxylipin concentration in plasma (pg/mL) at baseline and endpoint (mean ± SD).
| Intervention (n = 20) Week 0 | Intervention (n = 20) Week 12 | Control (n = 18) Week 0 | Control (n = 18) Week 12 | p-Value 1 | |
|---|---|---|---|---|---|
| Derived from arachidonic acid | |||||
| 5-F2t-IsoP | 56.2 (±82.5) | 39.2 (±37.3) | 44.2 (±40.8) | 63.3 (±40.8) | 0.175 |
| 15-F2t-IsoP | 31.8 (±37.1) | 37.7 (±29.1) | 51.7 (±62.1) | 38 (±25.2) | 0.014 |
| PGF2a | 109.1 (±128.7) | 83.6 (±94.7) | 112.2 (±122.6) | 118.3 (±86.3) | 0.217 |
| 5-HETE | 179.9 (±158.8) | 189.4 (±124.1) | 197.4 (±130.8) | 234.2 (±114.2) | 0.675 |
| 8-HETE | 67.6 (±71.3) | 51.9 (±57.1) | 74.8 (±46.3) | 64.1 (±36.3) | 0.734 |
| 9-HETE | 178.3 (±161.8) | 153.3 (±138.7) | 166.3 (±95.0) | 222.4 (±192.2) | 0.069 |
| 11-HETE | 96.5 (±86.8) | 69.4 (±101.2) | 131.1 (±98.6) | 142.4 (±126.4) | 0.119 |
| 12-HETE | 112 (±52.9) | 129.2 (±103.3) | 150.5 (±64.1) | 141.9 (±52.9) | 0.303 |
| 15-HETE | 139 (±106.8) | 143.8 (±95.3) | 153.5 (±77.3) | 170 (±84.1) | 0.696 |
| 20-HETE | 337.1 (±240.6) | 263.5 (±147.9) | 375.7 (±218.2) | 299.8 (±178.3) | 0.588 |
| Derived from docosahexaenoic acid | |||||
| 4-F4-NeuroP | 3890 (±3880) | 4785 (±4415) | 5388 (±5202) | 4701 (±4322) | 0.339 |
| 4-HDHA | 349 (±246.8) | 462.2 (±512.8) | 368.9 (±390.0) | 374.1 (±345.4) | 0.696 |
| 7-HDHA | 245.6 (±226.5) | 303.9 (±288.8) | 262.7 (±300.1) | 279.6 (±403.6) | 0.812 |
| 11-HDHA | 704.6 (±938.6) | 950.6 (±1625.0) | 576.7 (±458.6) | 743.1 (±666.3) | 0.217 |
| 14-HDHA | 4155 (±5985) | 6220 (±12320) | 4644 (±6696) | 5349 (±6390) | 0.800 |
| 17-HDHA | 2205 (±1289) | 3355 (±3557) | 2734 (±2452) | 2470 (±1918) | 0.426 |
HDHA, hydroxydocosahexanenoic acids; HETE, hydroxyeicosatetraenoic acids; IsoP, isoprostanoids; PGF, prostaglandins; 1—p-values comparing fold changes in intervention and control groups during the 12-week intervention using Mann–Whitney’s U-test; bold marks significant values.